Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators.

Lancet. 2007 Dec 22;370(9605):2103-11.

PMID:
18156031
2.

Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma.

Frampton JE, Keating GM.

BioDrugs. 2008;22(2):113-20. Review.

PMID:
18345708
3.

Immunotherapy for advanced renal cell cancer.

Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425. Review. Update in: Cochrane Database Syst Rev. 2015;12:CD001425.

PMID:
15674877
4.

Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.

McDermott DF, George DJ.

Cancer Treat Rev. 2010 May;36(3):216-23. doi: 10.1016/j.ctrv.2009.12.003. Epub 2010 Jan 29. Review.

PMID:
20116176
5.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

6.
7.

Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.

Iacovelli R, Alesini D, Palazzo A, Trenta P, Santoni M, De Marchis L, Cascinu S, Naso G, Cortesi E.

Cancer Treat Rev. 2014 Mar;40(2):271-5. doi: 10.1016/j.ctrv.2013.09.003. Epub 2013 Sep 11. Review.

PMID:
24070900
8.

Tolerability of first-line therapy for metastatic renal cell carcinoma.

Porta C, Szczylik C.

Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26. Review.

PMID:
19249157
9.

Targeted therapy for advanced renal cell carcinoma.

Coppin C, Le L, Porzsolt F, Wilt T.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006017. doi: 10.1002/14651858.CD006017.pub2. Review.

PMID:
18425931
10.

Treatment options for metastatic renal cell carcinoma: a review.

Athar U, Gentile TC.

Can J Urol. 2008 Apr;15(2):3954-66. Review.

PMID:
18405442
11.

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.

Thompson Coon JS, Liu Z, Hoyle M, Rogers G, Green C, Moxham T, Welch K, Stein K.

Br J Cancer. 2009 Jul 21;101(2):238-43. doi: 10.1038/sj.bjc.6605167. Epub 2009 Jun 30. Review.

12.

[First-line therapy of metastatic renal cell carcinoma--update 2009].

Miller K.

Onkologie. 2010;33 Suppl 1:5-9. doi: 10.1159/000265688. Epub 2010 Jan 22. Review. German.

13.

Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.

Escudier B, Cosaert J, Pisa P.

Expert Rev Anticancer Ther. 2008 Oct;8(10):1545-57. doi: 10.1586/14737140.8.10.1545. Review.

PMID:
18925847
14.

Bevacizumab: in first-line treatment of metastatic breast cancer.

Scott LJ.

Drugs. 2007;67(12):1793-9. Review.

PMID:
17683175
15.

Bevacizumab for patients with metastatic renal cancer: an update.

Yang JC.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6367S-70S. Review.

16.

Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.

Escudier B, Albiges L.

Drugs. 2011 Jun 18;71(9):1179-91. doi: 10.2165/11591410-000000000-00000. Review.

PMID:
21711062
17.

The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

Roviello G, Bachelot T, Hudis CA, Curigliano G, Reynolds AR, Petrioli R, Generali D.

Eur J Cancer. 2017 Apr;75:245-258. doi: 10.1016/j.ejca.2017.01.026. Epub 2017 Feb 24. Review.

PMID:
28242502
18.

The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.

Sonpavde G, Bellmunt J, Schutz F, Choueiri TK.

Curr Oncol Rep. 2012 Aug;14(4):295-306. doi: 10.1007/s11912-012-0237-9. Review.

PMID:
22532265
19.

[Current state of systemic therapy of metastatic renal cell carcinoma].

Merseburger AS, Waalkes S, Kuczyk MA.

Urologe A. 2009 Sep;48(9):983-4, 986, 988-9. doi: 10.1007/s00120-009-2072-7. Review. German.

PMID:
19669118
20.

Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review.

Smaletz O.

Int Braz J Urol. 2015 Sep-Oct;41(5):835-43. doi: 10.1590/S1677-5538.IBJU.2014.0651. Review.

Supplemental Content

Support Center